DOW
DOW INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$40.0B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
27.3%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-7.7%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
DOW
Recent performance trends
DOW
Cash flow trends
Consolidated indicators (7 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$55.0 billion | US$56.9 billion | US$44.6 billion | US$43.0 billion | US$40.0 billion |
| Total assets | US$63.0 billion | US$60.6 billion | US$58.0 billion | US$57.3 billion | US$58.5 billion |
| Shareholders' equity | US$18.2 billion | US$20.7 billion | US$18.6 billion | US$17.4 billion | US$16.0 billion |
| Net cash provided by (used in) operating activities | US$7.0 billion | US$7.5 billion | US$5.2 billion | US$2.9 billion | US$1.0 billion |
| Net cash provided by (used in) investing activities | US$-2.9 billion | US$-3.0 billion | US$-2.9 billion | US$-2.4 billion | US$-2.1 billion |
| Net cash provided by (used in) financing activities | US$-6.1 billion | US$-3.4 billion | US$-3.1 billion | US$-1.2 billion | US$2.5 billion |
| Cash and cash equivalents | US$3.0 billion | US$3.9 billion | US$3.0 billion | US$2.2 billion | US$3.8 billion |
Revenue scale in the same industry
DOW
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 3 companies
- 7 BRISTOL-MYERS SquibbFY Dec 2025 US$48.2B
- 8 Abbott LaboratoriesFY Dec 2025 US$44.3B
- 9 DOWThis companyFY Dec 2025 US$40.0B
- 10 AmgenFY Dec 2025 US$36.8B
- 11 Lyondellbasell Industries N.VFY Dec 2025 US$30.2B
- … 45 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$2.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$3.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$2.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-2.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.0 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$2.8 billion | Consolidated | Disclosed |
| Dividends paid | US$1.5 billion | Consolidated | Disclosed |
| Number of employees | 35,700 | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$17.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$1.5 billion | Consolidated | Disclosed |
| Net assets | US$16.0 billion | Consolidated | Disclosed |
| Net sales | US$40.0 billion | Consolidated | Disclosed |
| Total assets | US$58.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0 | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 27.3% | Consolidated | Calculated |
| Net margin | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |